22.65  3.08 (15.74%)		12-15 15:59
Open: 22.92 High: 25.3 Volume: 12,543,862		Pre. Close: 19.57 Low: 21.22 Market Cap: 2,077(M)

Short term
Mid term
Targets	6-month :	29.55	1-year :	34.51
Resists	First :	25.29	Second :	29.55
Pivot price	19.28
Supports	First :	19.21	Second :	15.46
MAs	MA(5) :	20.21	MA(20) :	18.95
	MA(100) :	13.61	MA(250) :	0
MACD	MACD :	1.1	Signal :	0.9
%K %D	K(14,3) :	68.3	D(3) :	73.5
RSI	RSI(14): 70.3
52-week	High :	25.29	Low :	5.15

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ IMNM ] has closed It is unclear right now based on current values. 54.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	25.33 - 25.44	25.44 - 25.53
Low:	21 - 21.1	21.1 - 21.19
Close:	22.49 - 22.65	22.65 - 22.8

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Tue, 16 Dec 2025
Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Tue, 16 Dec 2025
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - ts2.tech

Mon, 15 Dec 2025
Immunome’s Phase III Varegacestat Data Show Best-In-Class Potential In Desmoid Tumors - Citeline News & Insights

Mon, 15 Dec 2025
Why Immunome Stock Surged Today - Finviz

Mon, 15 Dec 2025
Immunome plans to offer $400 million in common stock shares By Investing.com - Investing.com South Africa

Mon, 15 Dec 2025
Immunome Announces Proposed Public Offering of Common Stock - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	92 (M)
Held by Insiders	7.517e+007 (%)
Held by Institutions	9.4 (%)
Shares Short	15,090 (K)
Shares Short P.Month	0 (K)

EPS	-2.0456e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	137.1 %
Return on Equity (ttm)	-46.5 %
Qtrly Rev. Growth	9.68e+006 %
Gross Profit (p.s.)	0
Sales Per Share	-42.68
EBITDA (p.s.)	-7.55642e+007
Qtrly Earnings Growth	-3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-185 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.54
Price to Cash Flow	17.14

Dividend	0
Forward Dividend	1.527e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.